Tests home telerehabilitation for adults receiving CAR-T therapy for lymphoma or myeloma
Tests guided home exercise and nutrition in adults with lymphoma or myeloma receiving CAR-T.
Plain-language title generated from the registry record
Registry title: Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Key facts
- Where
- Salt Lake City, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lymphoma or myeloma who are planning to have commercial CAR-T cell treatment. They would do a home-based exercise and nutrition program guided online.
- Age
- Older than 21 years.
- Sex
- All sexes can join.
- Disease stage
- Confirmed lymphoma or myeloma. Daily activity level (ECOG performance status) of 0-2.
- Earlier treatment
- Commercial FDA-approved CAR-T treatment must be planned for at least 4 weeks after joining.
Main reasons for not taking part
- Unstable angina, uncontrolled high blood pressure, or a recent heart attack
- A pacemaker
- Painful or unstable bone metastases, or recent bone fractures
- Already in a regular exercise rehabilitation program
- Plans to move within the next 6 months, or taking part in another clinical trial
Read by machine on 9 November 2026.
Where in United States
- Huntsman Cancer Institute at University of UtahSalt Lake City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Utah
- Trial code
- NCT07390071
- Record updated
- 5 February 2026
- Original description
The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and interactive education and empowerment. The design of the telerehabilitation system is based on the cloud-based Internet-of-Things architecture allowing real-time monitoring of cardiovascular parameters and exercise performance. The patient's level of exertion during exercise is automatically identified by a validated AI-driven algorithm supporting exercise safety and efficacy. The ultimate goal of this pilot feasibility project is to establish the extent of the impact of the proposed patient-centered cancer telerehabilitation model on disease-specific quality of life, and functional and symptom outcomes and to obtain sufficient evidence for a definitive randomized clinical trial evaluating this approach in a multi-center study.Read full original descriptionShow less
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and interactive education and empowerment. The design of the telerehabilitation system is based on the cloud-based Internet-of-Things architecture allowing real-time monitoring of cardiovascular parameters and exercise performance. The patient's level of exertion during exercise is automatically identified by a validated AI-driven algorithm supporting exercise safety and efficacy. The ultimate goal of this pilot feasibility project is to establish the extent of the impact of the proposed patient-centered cancer telerehabilitation model on disease-specific quality of life, and functional and symptom outcomes and to obtain sufficient evidence for a definitive randomized clinical trial evaluating this approach in a multi-center study.
Inclusion: age >21; confirmed diagnosis of lymphoma or myeloma; commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment; Eastern Cooperative Oncology Group (ECOG) performance status 0-2; Access to a working telephone line in their home or a cell phone.
Exclusion: have unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures; are engaged in a regular exercise rehabilitation program; have relocation plans within next 6 months; participate in another clinical trial.